Comparison of Age (<75 Years Vs ≥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study).
暂无分享,去创建一个
G. Stone | A. Kirtane | G. Weisz | R. Mehran | B. Claessen | M. Faggioni | B. Witzenbichler | B. Redfors | A. Crowley | S. Farhan | I. Mastoris | A. Maehara | P. Généreux | O. Ben‐Yehuda | O. Ben-Yehuda | Aaron Crowley
[1] M. Hadamitzky,et al. Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial , 2018, European heart journal.
[2] W. Qiu,et al. Gender Differences in Outcomes and Predictors of All-Cause Mortality After Percutaneous Coronary Intervention (Data from United Kingdom and Sweden). , 2017, The American journal of cardiology.
[3] Jun-Jie Zhang,et al. High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention , 2016, BMC Cardiovascular Disorders.
[4] E. Vicaut,et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial , 2016, The Lancet.
[5] N. Tang,et al. Advanced age and high‐residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor: comment , 2016, Journal of thrombosis and haemostasis : JTH.
[6] J. Spertus,et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. , 2016, JAMA.
[7] Chris I. Jones. Platelet function and ageing , 2016, Mammalian Genome.
[8] H. Suryapranata,et al. Advanced age and high‐residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor , 2016, Journal of thrombosis and haemostasis : JTH.
[9] Braunwald,et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.
[10] P. Noris,et al. Platelet count and aging , 2014, Haematologica.
[11] D. Atar,et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial , 2014, European heart journal.
[12] A. Kastrati,et al. Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age , 2014, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[13] Peter L Duffy,et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study , 2013, The Lancet.
[14] E. Vicaut,et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. , 2012, The New England journal of medicine.
[15] C. Cannon,et al. Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes: A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial , 2012 .
[16] P. Teirstein,et al. Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay Impact on Thrombosis and Safety (GRAVITAS) Trial , 2011, Circulation.
[17] Douglas R Seals,et al. Aging and vascular endothelial function in humans. , 2011, Clinical science.
[18] S. Pocock,et al. A risk score to predict bleeding in patients with acute coronary syndromes. , 2010, Journal of the American College of Cardiology.
[19] V. Deneer,et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. , 2010, JAMA.
[20] R. Koppensteiner,et al. Adenosine diphosphate‐inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel , 2010, Journal of thrombosis and haemostasis : JTH.
[21] A. Newman,et al. The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. , 2009, Clinics in geriatric medicine.
[22] P. Teirstein,et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. , 2009, American heart journal.
[23] F. Verheugt,et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. , 2009, Journal of the American College of Cardiology.
[24] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[25] J. Ware,et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial , 2007, The Lancet.
[26] B. Gersh,et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. , 2005, Journal of the American College of Cardiology.
[27] J. Fleg,et al. Secondary Prevention of Coronary Heart Disease in the Elderly (With Emphasis on Patients ≥75 Years of Age): An American Heart Association Scientific Statement From the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention , 2002, Circulation.
[28] S. Yusuf,et al. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. , 2001, Journal of the American College of Cardiology.
[29] Paul H. C. Eilers,et al. Flexible smoothing with B-splines and penalties , 1996 .
[30] Salim Yusuf,et al. Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.